Literature DB >> 18609275

Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction.

Serkan Cevdet Gokkaya1, Cuneyt Ozden, Ozdem Levent Ozdal, Hasbey Hakan Koyuncu, Ozer Guzel, Ali Memis.   

Abstract

OBJECTIVE: This study evaluated the effect of correction of serum cholesterol levels on erectile function and sildenafil treatment in patients with erectile dysfunction who have only hypercholesterolaemia as a risk factor for erectile dysfunction.
MATERIAL AND METHODS: Twenty-five patients with a single risk factor (hypercholesterolaemia, serum cholesterol > 200 mg/dl) for erectile dysfunction were included in the study. The patients were recommended to take sildenafil (minimum two 100 mg tablets/week) 1 h before sexual intercourse for 4 weeks. After 1 month washout period, the patients received a single dose of atorvastatin 10 mg/day for 1 month. Similarly, after a 1 month washout period, atorvastatin 10 mg/day and sildenafil (minimum two 100 mg tablets/week) were administered for 1 month as combination therapy. Erectile function was evaluated before and after all treatment regimens using the International Index of Erectile Function (IIEF).
RESULTS: Following each treatment modality mean IIEF scores were significantly higher than baseline IIEF scores (p < 0.01). The IIEF score after sildenafil treatment was significantly higher than in the atorvastatin treatment group (p < 0.01); and the IIEF score after combined treatment was significantly higher than in the sildenafil and atorvastatin treatment groups.
CONCLUSIONS: Correction of serum cholesterol levels with atorvastatin could improve erectile function in patients who have only hypercholesterolaemia as a risk factor for erectile dysfunction. Furthermore, atorvastatin could improve sildenafil's effects on erectile function in hypercholesterolaemic patients with erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18609275     DOI: 10.1080/00365590801950279

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  6 in total

1.  Statins and male sexual health: a retrospective cohort analysis.

Authors:  Richard Davis; Kelly R Reveles; Sayed K Ali; Eric M Mortensen; Christopher R Frei; Ishak Mansi
Journal:  J Sex Med       Date:  2014-11-25       Impact factor: 3.802

2.  Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study.

Authors:  Mehmet İlker Gokce; Ömer Gülpınar; Erdem Öztürk; Sadi Güleç; Önder Yaman
Journal:  Int Urol Nephrol       Date:  2012-01-18       Impact factor: 2.370

3.  The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease.

Authors:  Ajay Nehra; Graham Jackson; Martin Miner; Kevin L Billups; Arthur L Burnett; Jacques Buvat; Culley C Carson; Glenn R Cunningham; Peter Ganz; Irwin Goldstein; Andre T Guay; Geoff Hackett; Robert A Kloner; John Kostis; Piero Montorsi; Melinda Ramsey; Raymond Rosen; Richard Sadovsky; Allen D Seftel; Ridwan Shabsigh; Charalambos Vlachopoulos; Frederick C W Wu
Journal:  Mayo Clin Proc       Date:  2012-08       Impact factor: 7.616

4.  Treatment Strategy for Non-Responders to PDE5 Inhibitors.

Authors:  Nam Cheol Park; Tae Nam Kim; Hyun Jun Park
Journal:  World J Mens Health       Date:  2013-04-23       Impact factor: 5.400

5.  Rigiscan Evaluation of Men with Diabetes Mellitus and Erectile Dysfunction and Correlation with Diabetes Duration, Age, BMI, Lipids and HbA1c.

Authors:  Daniel Peter Andersson; Urban Ekström; Mikael Lehtihet
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

6.  Therapeutic potential of Mucuna pruriens (Linn.) on high-fat diet-induced testicular and sperm damage in rats.

Authors:  Anuradha Murugesan; Karthik Ganesh Mohanraj; Khayinmi Wungpam Shimray; Mohammad Zafar Iqbal Khan; Prakash Seppan
Journal:  Avicenna J Phytomed       Date:  2022 Sep-Oct
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.